IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,950 shares of the medical research company’s stock after selling 861 shares during the quarter. NewEdge Advisors LLC’s holdings in IQVIA were worth $3,724,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $33,000. Lee Danner & Bass Inc. purchased a new position in IQVIA during the 4th quarter worth $44,000. Zions Bancorporation N.A. lifted its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the period. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA during the fourth quarter worth about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 3.2 %

Shares of NYSE:IQV opened at $143.66 on Monday. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The stock has a 50-day simple moving average of $176.42 and a 200-day simple moving average of $196.40. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on IQV. UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Barclays reaffirmed an “equal weight” rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research report on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.